A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
A. Tan, A. Seet, S.P. Choo, D. Tai1, Y.C. Lam, W.T. Teng, C. Lim, K.H. Lim,
M. Ng; Division of Medical Oncology, National Cancer Centre Singapore,
Singapore, Singapore, Division of Clinical Trials and Epidemiological (CTE)
Sciences, National Cancer Centre Singapore, Singapore, Singapore, Department of
Pathology, Singapore General Hospital, Singapore, Singapore
ESMO (2019) Abstract 1311

JADETREE*: A phase 2A, single arm, multicenter, study of the panHER inhibitor varlitinib plus capecitabine in Chinese patients with advanced or metastatic biliary tract cancer (BTC).
Shukui Qin, Weijia Fang, Yuxian Bai, Xiufeng Liu, Yifu He, Jianping Xiong, Tao Zhang, Zhendong Chen, Ying Cheng, Wei Li, Jiwei Liu, Zhiqiang Meng, Hongming Pan, Guo-Ping Sun, Fuxiang Zhou, Chih-Yi Hsieh, Mark McHale
CSCO (2019) Abstract 

A multicentre, phase 1b/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naïve, advanced, or metastatic biliary tract cancer (BTC)
D.Y. Oh, W.P. Yong, L.T. Chen, J.W. Kim, A.Y. Chang, J.H. Park, C.Y. Hsieh, H.J. Shih, N. McIntyre, Y.C. Chen, W.L. Chang, M. McHale, B. Lindmark
ASCO GI (2019), Abstract Number: 319

Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies
A.C. Tan, D.Y. Oh, Y. Chao, C.Y. Hsieh, W.L. Chang, F. Isanto, Y.C. Chen, M. McHale, B. Lindmark, M. Ng
ASCO GI (2019), Abstract Number: 331

Phase I study safety and tolerability of Varlitinib (VAR) in combination with Oxaliplatin and Capecitabine (COX) or Oxaliplatin and 5-FU (FOL) in advanced solid tumours
A. Seet, P.C. Su, D. Tai, J. Lam, T.T. Wan, G. Ang, C. Lim, T. Lim, I. Tan, M. Ng
ESMO (2018), Abstract Number: 430P

Multicenter open label, randomized Phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy
S.C. Lee, S.C. Chen, M.S. Dai, G.E. Lee, C.L. Liu, A. Chen, H.K. Chang, L.M. Tseng, W.Y. Chay, L. Chow, P.J.  Lotus, K.M. Rau, H.C. Wang, A. Guancia, M. Head, J. Chiu, B. Robinson, M. McHale, A. Barge, B. Lindmark, N. McIntyre, C.Y. Hsieh
CSCO (2018), Abstract Number: 1148

JADETREE (Joint Assessment of Drug Efficacy of Pan-Her inhibition using Varlitinib in second line BTC in China ): A phase 2A, single arm, multicentre study of varlitinib plus capecitabine in Chinese patients with advanced or metastatic biliary tract cancer (BTC).
S. Qin, W. Fang, Y. Bai, X. Liu, Y. He, J. Xiong, T. Zhang, Z. Chen, Y. Cheng, W. Li, J. Liu, Z. Meng,
H. Pan, G.P. Sun, F. Zhou, B. Lindmark, H.J. Shih, C.Y. Hsieh, N. McIntyre, W.L. Chang
CSCO (2018), Abstract Number: C-12

TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).
M.M. Javle, D.Y. Oh, M. Ikeda, S. Qin, W.P. Yong, Y. Chao, N. McIntyre, C.Y. Hsieh, L. Chow, A. Chang, M. McHale, B. Lindmark .
ASCO (2018), Abstract Number: TPS4143.

Dose finding study of Varlitinib ± Trastuzumab with Carboplatin/Paclitaxel in advanced solid tumors.
M. Lee, A. Wong, S. Ow, R. Sundar, L.Z. Wang, D.S.P. Tan, R.A. Soo, C.E. Chee, V. Heong, Y.C. Chen, J.S.J. Lim, W.P. Yong, S.E. Lim, B.C. Goh, S.C. Lee.
ASCO (2018), Abstract Number: 2588.

Multicenter open label, randomized Phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy.
S.C. Lee, S.C. Chen, M.S. Dai, G.E. Lee, C.L. Liu, A. Chan, H.K. Chang, L.M. Tseng, W.Y. Chay, L.W.C. Chow, J.L. Peneyra, K.M. Rau, H.C. Wang, A.A. Guancia, M. Head, J.W.Y. Chiu, B. Robinson, M. McHale, A. Barge, B. Lindmark, N. McIntyre, C.Y. Hsieh.
ESMO Asia (2017), Abstract Number 102P.

Initial signals of efficacy in cholangiocarcinoma from a phase Ib trial of varlitinib in combination with doublet chemotherapy (cisplatin + 5-fluororacil or capecitabine).
C.Y. Hsieh, M.S. Wu, M. McHale, B. Lindmark, L. Chow, Y. Chao.
ASCO (2017), Abstract Number e15671.

Pan-HER inhibitor, varlitinib (ASLAN001) disrupts HER/ERK signaling and causes apoptosis in triple negative breast cancer cells.
C.Y. Liu, T.T. Huang, C.T. Huang,  H.P. Yang, L.M. Tseng, C.W. Shiau, K.F. Chen.
AACR (2017), Abstract Number 2087.

Varlitinib to demonstrate anti-tumour efficacy in patient-derived hepatocellular carcinoma xenograft models.
C.Y. Hsieh, L. Ooi, R. Ong, B. Lindmark, M. McHale, H.T. Huynh.
ASCO (2016), Abstract Number e15598.

Varlitinib demonstrates potent antitumour efficacy in patient-derived gastric cancer xenograft models.
H.T. Huynh, R. Ong, B. Lindmark, M. McHale, A.G.L. Ooi.
AACR (2016), Abstract Number 4719.

Phase IIA study to evaluate the biological activity of varlitinib (ASLAN001) in HER-1/2 co-expressing or HER-2 amplified advanced gastric cancer.
J. Kim, S. Im, K. Lee, J.W. Kim, K. Lee, S. Han, T. Kim, I.S. Choi, D. Oh, N. Lee, C. Song, M. Foster, M. McHale, A. Barge, W.H. Kim, Y. Bang
ESMO (2014), Abstract Number 664P.

Pan-ErbB inhibition by varlitinib (ARRY-334543) is superior to selective ErbB inhibition in a preclinical model that signals through multiple ErbB receptors.
R.Blackwell, K. Bouhana, S. Winski, P. Lee, J. Winkler, D. Walker, J. Garrus.
AACR (2010), Abstract Number 3610.

In vivo activity of varlitinib (ARRY-334543), a potent, small molecule inhibitor of EGFR/ErbB-2 in combination with trastuzumab, capecitabine or docetaxel.
D. Anderson, C. Napier, A. Avrutskaya, A. White, T. Pheneger, J. Winkler, P. Lee.
AACR (2009), Abstract Number 1757

Differential activity of varlitinib (ARRY-543), a potent, small molecule inhibitor of EGFR/ErbB2 compared to lapatinib in in vivo xenograft models.
K.Bouhana, T. Pheneger, R. Woessner, G. Tarlton, I.V. Carlowitz, K. Hoffman, E. Wallace, K. Koch, J. Winkler, S. Winski, P. Lee.
AACR (2008). Abstract Number 4848.

In vivo activity of varlitinib (ARRY-334543), a potent, small molecule inhibitor of EGFR/ErbB-2 in combination with trastuzumab or docetaxel.
P.Lee, D. Anderson, A. Avrutskaya, A. White, T. Pheneger, J. Winkler.
CTRC-AACR San Antonio Breast Cancer Symposium (2008). Abstract Number 2150.

In vivo anti-tumour activity of varlitinib (ARRY-334543), a small molecule inhibitor of EGFR and ErbB-2.
T.Pheneger, R. Woessner, S. Winski, D. Anderson, J. Lyssikatos, B. Bernat, G. Miknis, G. Topalov, L. Ren, E. Wallace, P. Lee.
AACR-NCI-EORTC (2005). Abstract Number A247.

Varlitinib (ARRY-334543), a potent, orally active small molecule inhibitor of EGFR and ErbB-2.
G.Miknis, E. Wallace, J. Lyssikatos, P. Lee, Q. Zhao, J. Hans, G. Topalov, A. Buckmelter, G. Tarlton, L. Ren, J. Tullis, B. Bernat, L.P. Opie, I.V. Carlowitz, J. Parry, T. Morales, M. Perrier, R. Woessner, T. Pheneger, K. Hoffman, J. Winkler, K. Koch.
AACR (2005). Abstract Number 3399.

ASLAN003, a Novel and Potent Dihydroorotate Dehydrogenase (DHODH) Inhibitor, Induces Differentiation of Acute Myeloid Leukemia
J. Zhou, J.Y. Quah, J.Y. Chooi, S.H. Toh, B. Lin, M. Osato, Q. Seet, L. Ooi, B. Lindmark, M. McHale, W.J. Chng
ASH (2018), Poster number: 4047

Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity
S.B. Ting, C.H. Ng, A. Bajel, W.Y.K. Hwang, H.J. Shih, W.J. Chng, M. McHale, C.Y. Hsieh, H.J. Shih, N. McIntyre, J. Kwek , W.L. Chang, B. Lindmark.
ASH (2018), Poster number: 2676

A phase IIa dose optimization study of ASLAN003 in Acute Myeloid Leukemia (AML)
C.H. Ng, S.B. Ting, W.Y.K. Hwang, A. Bajel, R. Eek, M. McHale, H.-J. Shih, N. McIntyre, J. Kwek , B. Lindmark.
ESMO (2018), Abstract number: 1043TiP

Related Publications
Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer.
K.K. Brown, J.B. Spinelli, J.M. Asara, A. Toker.
Cancer Discovery (2017), 7(4), 1-9.

PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to dihydroorotate dehydrogenase inhibition.
Mathur, E. Stratikopoulos, S. Ozturk, N. Steinbach, S. Pegno, S. Schoenfeld, R. Yong, V.V. Murty, J.M. Asara, L.C. Cantley, R. Parsons.
Cancer Discovery (2017), 7(4), 380-390.

Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
D.B. Sykes, Y.S. Kfoury, F.E. Mercier, M.J. Wawer, J.M. Law, M.K. Haynes, T.A. Lewis, A. Schajnovitz, E. Jain, D. Lee, H. Meyer, K.A. Pierce, N.J. Tolliday, A. Waller, S.J. Ferrara, A.L. Eheim, D. Stoeckigt, K.L. Maxcy, J.M. Cobert, J. Bachand, B.A. Szekely, S. Mukherjee, L.A. Sklar, J.D. Kotz, C.B. Clish, R.I. Sadreyev, P.A. Clemons, A. Janzer, S.L. Schreiber, D.T. Scadden.
Cell (2016), 167, 1-16.

The Role of Dihydroorotate Dehydrogenase in Apoptosis Induction in Response to Inhibition of the Mitochondrial Respiratory Chain Complex III.
A.A. Khutornenko, A.A. Dalina, B.V. Chernyak, P.M. Chumakov, A.G. Evstafieva.
Acta Naturae (2014), 6(1), 69-75.

Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway.
A.A. Khutornenko, V.V. Roudko, B.V. Chernyak, A.B. Vartapetian, P.M. Chumakov, A.G. Evstafieva.
PNAS (2010), 107(29), 12828-12833.

RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis.
Andrade, J. Fornetti, L. Zhao, S.C. Miller, R.L. Randall, N. Anderson, S.E. Waltz, M. McHale, A.L. Welm.
Science Translational Medicine (2017), 9(374), eaai9338.

Pre-clinical efficacy of RON kinase inhibitors alone and in combination with PI3K inhibitors for treatment of sfRon-expressing breast cancer patient-derived xenografts.
M. Bieniasz, P. Radhakrishnan, N. Faham, J-P. De La O, A. L. Welm.
Clinical Cancer Research (2015), 21 (16); doi: 10.1158/1078-0432.CCR-14-3283  

Inhibition of Ron Kinase Blocks Conversion of Micrometastases to Overt Metastases by Boosting Antitumor Immunity.
H. Eyob, H.A. Ekiz, Y.S. DeRose, S.E. Waltz, M.A. Williams, A.L. Welm
Cancer Discovery 2013, 3, 751-760.

RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses.
H. Eyob, H.A. Ekiz, A.L. Welm
Oncoimmunology (2013), 2(9), e25670.

RON’s new role.
C. Cain
SciBX 6(21); doi: 10.1038/scibx.2013.507